We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.34B
AUM Growth
+$471M
Cap. Flow
+$471M
Cap. Flow %
20.11%
Top 10 Hldgs %
49.6%
Holding
148
New
13
Increased
17
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$59.2M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$51.5M
3
SWTX
SpringWorks Therapeutics
SWTX
+$33.1M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$25.3M
5
KLRS
Kalaris Therapeutics
KLRS
+$22M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$92.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$87.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$28.5M
4
CYTK icon
Cytokinetics
CYTK
+$13.2M
5
BLU
BELLUS Health Inc.
BLU
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 77.68%
2 Consumer Discretionary 2.9%
3 Financials 0.65%
4 Consumer Staples 0.17%
5 Industrials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$397M 16.93%
+5,000,000
New +$422M
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$215M 9.2%
89,778,234
+18,599,870
+26% +$51.5M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$92.5M 3.95%
1,325,000
+225,000
+20% +$16.6M
ONC
4
BeOne Medicines Ltd
ONC
$34B
$87.6M 3.74%
650,000
– –
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$68.3M 2.91%
+1,000,000
New +$59.2M
BLU
6
DELISTED
BELLUS Health Inc.
BLU
$63.4M 2.7%
6,000,000
-1,000,000
-14% -$10.6M
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$60.8M 2.6%
2,150,000
+500,000
+30% +$13.9M
SRRK icon
8
Scholar Rock
SRRK
$5.97B
$60.6M 2.59%
8,750,034
– –
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
$58.6M 2.5%
2,053,403
+1,153,403
+128% +$33.1M
FATE icon
10
Fate Therapeutics
FATE
$267M
$58.3M 2.49%
2,600,000
– –
WW
11
DELISTED
WW International
WW
$58.2M 2.49%
14,818,300
– –
CERE
12
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$56.5M 2.41%
2,000,000
+500,000
+33% +$14.9M
IGMS
13
DELISTED
IGM Biosciences
IGMS
$55.7M 2.38%
2,450,000
+450,000
+23% +$9.09M
ARGX icon
14
argenx
ARGX
$55.4B
$53M 2.26%
150,000
-250,000
-63% -$92.6M
CYTK icon
15
Cytokinetics
CYTK
$10.8B
$48.5M 2.07%
1,000,000
-275,000
-22% -$13.2M
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$47.9M 2.04%
350,000
-175,000
-33% -$28.5M
KLRS
17
Kalaris Therapeutics
KLRS
$79.7M
$44M 1.88%
242,486
+141,470
+140% +$22M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$41.8M 1.78%
4,000,000
– –
GOSS icon
19
Gossamer Bio
GOSS
$97.2M
$38.9M 1.66%
3,246,624
+887,656
+38% +$11M
SEER icon
20
Seer Inc
SEER
$115M
$36.8M 1.57%
4,750,000
– –
KRYS icon
21
Krystal Biotech
KRYS
$10.7B
$34.9M 1.49%
500,000
– –
KYMR icon
22
Kymera Therapeutics
KYMR
$8.64B
$32.7M 1.39%
1,500,000
+500,000
+50% +$13.2M
RLAY icon
23
Relay Therapeutics
RLAY
$3.95B
$32.5M 1.39%
1,454,716
+754,716
+108% +$16.6M
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$29.4M 1.25%
750,000
+300,000
+67% +$11.6M
KRTX
25
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$28.1M 1.2%
+125,000
New +$25.3M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2022 Portfolio in Review

As of Q3 2022, Artal Group held 148 positions worth $2.34B, up 25% from $1.87B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $471M of net new capital in Q3 2022, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was argenx, an estimated $92.6M trimmed.

  • Artal Group's largest Q3 2022 buy was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q3 2022, an estimated $51.5M increase.
  • Artal Group's biggest Q3 2022 reduction was argenx, cutting an estimated $92.6M.
  • Artal Group fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $87.5M.
  • Artal Group's ten largest holdings make up 50% of its $2.34B portfolio in Q3 2022.
  • Artal Group opened 13 new positions and closed 13 in Q3 2022.
  • Artal Group's portfolio value rose 25% quarter-over-quarter to $2.34B.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.